Yoshiro Sakamoto

Severe and Prolonged Hypoglycemia Following Adrenalectomy for Pheochromocytoma: A Case Report

Masahiko Kawasumi, Yoshiro Sakamoto, Yuka Tosaka, Yukiko Okazaki

We report a case of a 64-year-old woman with poorly controlled diabetes mellitus who was found to have a left adrenal pheochromocytoma. Despite standard preoperative management including alpha-blockade with doxazosin, the patient developed persistent and severe hypoglycemia immediately following adrenalectomy, requiring high-rate …

jp (code pays fourni par la source)

Bone scan index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastases

Hisashi Hirano, Masayoshi Nagata, Naoya Nagaya, So Nakamura et autres

Reports of Bone Scan Index (BSI) calculations as imaging biomarkers to predict survival in patients with metastatic castration-resistant prostate cancer (mCRPC) have been mainly from retrospective studies. To evaluate the effectiveness of enzalutamide (ENZ) in Japanese patients with mCRPC and bone metastases …

jp (code pays fourni par la source)

Supplementary Figure 2A from Hypoxia-Inducible Protein 2 (HIG2), a Novel Diagnostic Marker for Renal Cell Carcinoma and Potential Target for Molecular Therapy

Akira Togashi, Toyomasa Katagiri, Shingo Ashida, Tomoaki Fujioka et autres

Supplementary Figure 2A from Hypoxia-Inducible Protein 2 (HIG2), a Novel Diagnostic Marker for Renal Cell Carcinoma and Potential Target for Molecular Therapy

Supplementary Figure 2B from Hypoxia-Inducible Protein 2 (HIG2), a Novel Diagnostic Marker for Renal Cell Carcinoma and Potential Target for Molecular Therapy

Akira Togashi, Toyomasa Katagiri, Shingo Ashida, Tomoaki Fujioka et autres

Supplementary Figure 2B from Hypoxia-Inducible Protein 2 (HIG2), a Novel Diagnostic Marker for Renal Cell Carcinoma and Potential Target for Molecular Therapy

Supplementary Figure 1B from Hypoxia-Inducible Protein 2 (HIG2), a Novel Diagnostic Marker for Renal Cell Carcinoma and Potential Target for Molecular Therapy

Akira Togashi, Toyomasa Katagiri, Shingo Ashida, Tomoaki Fujioka et autres

Supplementary Figure 1B from Hypoxia-Inducible Protein 2 (HIG2), a Novel Diagnostic Marker for Renal Cell Carcinoma and Potential Target for Molecular Therapy

Supplementary Figure 1A from Hypoxia-Inducible Protein 2 (HIG2), a Novel Diagnostic Marker for Renal Cell Carcinoma and Potential Target for Molecular Therapy

Akira Togashi, Toyomasa Katagiri, Shingo Ashida, Tomoaki Fujioka et autres

Supplementary Figure 1A from Hypoxia-Inducible Protein 2 (HIG2), a Novel Diagnostic Marker for Renal Cell Carcinoma and Potential Target for Molecular Therapy

Five Supplementary Tables from Hypoxia-Inducible Protein 2 (HIG2), a Novel Diagnostic Marker for Renal Cell Carcinoma and Potential Target for Molecular Therapy

Akira Togashi, Toyomasa Katagiri, Shingo Ashida, Tomoaki Fujioka et autres

Five Supplementary Tables from Hypoxia-Inducible Protein 2 (HIG2), a Novel Diagnostic Marker for Renal Cell Carcinoma and Potential Target for Molecular Therapy

Supplementary Figure 4 from Hypoxia-Inducible Protein 2 (HIG2), a Novel Diagnostic Marker for Renal Cell Carcinoma and Potential Target for Molecular Therapy

Akira Togashi, Toyomasa Katagiri, Shingo Ashida, Tomoaki Fujioka et autres

Supplementary Figure 4 from Hypoxia-Inducible Protein 2 (HIG2), a Novel Diagnostic Marker for Renal Cell Carcinoma and Potential Target for Molecular Therapy

Supplementary Figure 3A-C from Hypoxia-Inducible Protein 2 (HIG2), a Novel Diagnostic Marker for Renal Cell Carcinoma and Potential Target for Molecular Therapy

Akira Togashi, Toyomasa Katagiri, Shingo Ashida, Tomoaki Fujioka et autres

Supplementary Figure 3A-C from Hypoxia-Inducible Protein 2 (HIG2), a Novel Diagnostic Marker for Renal Cell Carcinoma and Potential Target for Molecular Therapy

Supplementary Table 4 from Hypoxia-Inducible Protein 2 (HIG2), a Novel Diagnostic Marker for Renal Cell Carcinoma and Potential Target for Molecular Therapy

Akira Togashi, Toyomasa Katagiri, Shingo Ashida, Tomoaki Fujioka et autres

Supplementary Table 4 from Hypoxia-Inducible Protein 2 (HIG2), a Novel Diagnostic Marker for Renal Cell Carcinoma and Potential Target for Molecular Therapy

Supplementary Table 5 from Hypoxia-Inducible Protein 2 (HIG2), a Novel Diagnostic Marker for Renal Cell Carcinoma and Potential Target for Molecular Therapy

Akira Togashi, Toyomasa Katagiri, Shingo Ashida, Tomoaki Fujioka et autres

Supplementary Table 5 from Hypoxia-Inducible Protein 2 (HIG2), a Novel Diagnostic Marker for Renal Cell Carcinoma and Potential Target for Molecular Therapy

Supplementary Table 3 from Hypoxia-Inducible Protein 2 (HIG2), a Novel Diagnostic Marker for Renal Cell Carcinoma and Potential Target for Molecular Therapy

Akira Togashi, Toyomasa Katagiri, Shingo Ashida, Tomoaki Fujioka et autres

Supplementary Table 3 from Hypoxia-Inducible Protein 2 (HIG2), a Novel Diagnostic Marker for Renal Cell Carcinoma and Potential Target for Molecular Therapy